Trials / Completed
CompletedNCT01396434
Safety Surveillance of Pneumococcal 13-valent Conjugate Vaccine Among Filipinos
A Non-interventional Study Of The Safety Of Pneumococcal 13-valent Conjugate Vaccine (Prevenar 13) In The Philippines: A Post Marketing Surveillance Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,006 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 6 Weeks
- Healthy volunteers
- Accepted
Summary
Prevenar 13 is safe for administration to Filipinos.
Detailed description
Filipino patients prescribed and administered with the vaccine will be monitored for safety Patients prescribed with the vaccine who provides consent for inclusion to the study will be observed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Prevenar 13 | Prevenar 13 vaccine as prescribed by the physician based on approved product indication |
Timeline
- Start date
- 2011-12-01
- Primary completion
- 2014-05-01
- Completion
- 2014-05-01
- First posted
- 2011-07-18
- Last updated
- 2017-01-30
- Results posted
- 2017-01-30
Locations
119 sites across 1 country: Philippines
Source: ClinicalTrials.gov record NCT01396434. Inclusion in this directory is not an endorsement.